Literature DB >> 9114152

Mycobacterium xenopi: innocent bystander or emerging pathogen?

T M Jiva1, H M Jacoby, L A Weymouth, D A Kaminski, A C Portmore.   

Abstract

Mycobacterium xenopi is a recognized cause of smoldering pulmonary disease in patients with chronic lung disease. This organism is frequently isolated from respiratory specimens from individuals infected with human immunodeficiency virus (HIV) and is often considered nonpathogenic. Cases of pulmonary and disseminated M. xenopi disease have been described in patients with HIV infection and other immunodeficiencies. Many physicians are unaware of the clinical significance of M. xenopi isolation. Whether this organism represents a commensal or a pathogen capable of causing considerable morbidity and mortality is not fully understood. In this study, we investigated the clinical significance of M. xenopi isolation and explored the clinical spectrum of M. xenopi disease. Clinical illness occurred both in elderly people with chronic lung disease and in young individuals with HIV infection. The repeated isolation of M. xenopi in association with pulmonary lesions suggests significant infection and mandates further workup and therapy.

Entities:  

Mesh:

Year:  1997        PMID: 9114152

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

1.  Nontuberculous Mycobacterial Infections of the Lung.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

2.  Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003.

Authors:  Theodore K Marras; Pamela Chedore; Alicia M Ying; Frances Jamieson
Journal:  Thorax       Date:  2007-02-20       Impact factor: 9.139

3.  Isolation prevalence of pulmonary nontuberculous mycobacteria in Ontario in 2007.

Authors:  Mohammed Al Houqani; Frances Jamieson; Pamela Chedore; Mauli Mehta; Kevin May; Theodore K Marras
Journal:  Can Respir J       Date:  2011 Jan-Feb       Impact factor: 2.409

4.  Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept.

Authors:  Nimrod Maimon; James Brunton; Adrienne Chan; Theodore K Marras
Journal:  BMJ Case Rep       Date:  2009-02-02

5.  Differential requirement for interferon-gamma to restrict the growth of or eliminate some recently identified species of nontuberculous mycobacteria in vivo.

Authors:  S Ehlers; E Richter
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

6.  Spondylitis due to Mycobacterium xenopi in a human immunodeficiency virus type 1-infected patient: case report and review of the literature.

Authors:  Agnès Meybeck; Claude Fortin; Sophie Abgrall; Homa Adle-Biassette; Gilles Hayem; Raymond Ruimy; Patrick Yeni
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

7.  Pulmonary Mycobacterium xenopi infection in AIDS patients treated with HAART in Hungary.

Authors:  J Szlávik; C Sárvári
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-14       Impact factor: 3.267

8.  Mycobacterium xenopi and drinking water biofilms.

Authors:  M Dailloux; M Albert; C Laurain; S Andolfatto; A Lozniewski; P Hartemann; L Mathieu
Journal:  Appl Environ Microbiol       Date:  2003-11       Impact factor: 4.792

9.  Mycobacterium heckeshornense infection in an immunocompetent patient and identification by 16S rRNA sequence analysis of culture material and a histopathology tissue specimen.

Authors:  Rob van Hest; Adri van der Zanden; Martin Boeree; Kristin Kremer; Mirjam Dessens; Pieter Westenend; Boulos Maraha; René van Uffelen; Ronald Schütte; Wiel de Lange
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

10.  Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept.

Authors:  Nimrod Maimon; James Brunton; Adrienne K Chan; Theodore K Marras
Journal:  Thorax       Date:  2007-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.